MC-1 (pyridoxal 5′-phosphate): novel therapeutic applications to reduce ischaemic injury

Author： Kandzari David E   Dery Jean-Pierre   Armstrong Paul W   Douglas Deborah A   Zettler Marjorie E   Hidinger G Karl-Gunnar   Friesen Albert D   Harrington Robert A  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.11, 2005-11, pp. : 1435-1442

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pyridoxal 5'-Phosphate Enzymes as Targets for Therapeutic Agents

By  

Current Medicinal Chemistry, Vol. 14, Iss. 12, 2007-05 ,pp. : 1291-1324

Bentham Science Publishers

Access to resources Recommend Favorite

The novel pyridoxal-5'-phosphate derivative PPNDS potently antagonizes activation of P2X 1 receptors

By Lambrecht G.   Rettinger J.   Baumert H.G.   Czeche S.   Damer S.   Ganso M.   Hildebrandt C.   Niebel B.   Spatz-Kumbel G.   Schmalzing G.   Mutschler E.  

European Journal of Pharmacology, Vol. 387, Iss. 3, 2000-01 ,pp. : 19-21

Elsevier

Access to resources Recommend Favorite

Inhibition of post-ischaemic inflammation as a therapeutic approach to myocardial ischaemia reperfusion injury

By Kupatt C.   Wichels R.   Becker B.   Boekstegers P.  

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 9, 2000-09 ,pp. : 1395-1404

Informa Healthcare

Access to resources Recommend Favorite

Structure-Activity Relationships of Suramin and Pyridoxal-5'-phosphate Derivatives as P2 Receptor Antagonists

By  

Current Pharmaceutical Design, Vol. 8, Iss. 26, 2002-12 ,pp. : 2371-2399

Bentham Science Publishers

Access to resources Recommend Favorite

SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease

By  

Current Drug Targets, Vol. 18, Iss. 15, 2017-10 ,pp. : 1746-1753

Bentham Science Publishers

Access to resources Recommend Favorite